NCT03850522View on ClinicalTrials.gov

PD-L1 Peptide Vaccination in High Risk Smoldering Multiple Myeloma

PHASE2TerminatedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

February 18, 2019

Primary Completion Date

March 10, 2021

Study Completion Date

March 10, 2021

Conditions
Smoldering Multiple Myeloma
Interventions
BIOLOGICAL

PD-L1 peptide

PD-L1 peptide (100 micrograms) emulsified with the adjuvant Montanide ISA-51 given subcutaneously 10 times every second week over the course of 26 weeks including a five-week break.

Trial Locations (1)

2730

Department of Hematology, Universityhospital Herlev and Gentofte, Herlev

Sponsors

Collaborators (1)

IO Biotech
All Listed Sponsors
collaborator

IO Biotech

INDUSTRY

lead

Lene Meldgaard Knudsen

OTHER

NCT03850522 - PD-L1 Peptide Vaccination in High Risk Smoldering Multiple Myeloma | Biotech Hunter | Biotech Hunter